Childhood Leukemia
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 45988
Special Issue Editors
Interests: childhood leukemia; hematological malignancies; transcriptional regulation; gene expression; epigenetics; signal transduction; tumor suppression; targeted therapy; acute lymphoblastic leukemia; combination therapies
Interests: translational cancer research; pharmacogenomics; cancer genetics; medical biochemistry; clinical pharmacology; clinical genetics; diabetes genetics; nanomedicine; bile acid research; oxidative medicine
Special Issue Information
Dear Colleagues,
Childhood leukemia is the most common malignancy in children. It encompasses several types of hematological malignancy, each with unique pathogeneses and treatment strategies. Over the past 70 years, we have witnessed tremendous progress towards understanding the mechanisms of leukemogenesis and developing novel treatments for these diseases.
The discovery of tumor suppressors, as well as oncogenes that act as major drivers of malignant transformation, provided insights into the transcriptional network and signaling pathways that regulate gene expression in leukemia. The use of next-generation sequencing furthered our understanding of the molecular mechanisms of malignant transformation and relapse, discovery of novel biomarkers, and ultimately to the development of a molecular classification of leukemia, with the identification of novel subtypes of high-risk leukemia (e.g., Ph-like B-cell acute lymphoblastic leukemia).
Clinical research led by clinical trial groups resulted in advanced therapeutic protocols. The development of targeted therapy as well as immunotherapy with chimeric antigen receptor T cells (CAR-T cell therapy) paved the way to a precision medicine approach. Advances in stem cell transplant protocols and techniques led to an improved outcome following this procedure. The above-described research advances improved the treatment and overall prognosis of childhood leukemia, resulting in a current 5-year survival rate of 83.6% for pediatric leukemia, as compared to less than 37% survival in 1975.
There are currently challenges associated with elucidating the basic mechanisms of the malignant transformation, progression, and development of chemotherapy resistance in childhood leukemia. Clinically, further improvement of overall survival, understanding the long-term effects of chemotherapy, reducing racial health disparities in childhood leukemia, and advancing immunotherapy and stem cell transplantation are only some of the current challenges in this field.
This Special Issue will highlight the basic, translational, and clinical aspects of childhood leukemia, along with the latest advances and future directions in understanding molecular mechanisms of pathogenesis, clinical presentation, and treatment of these diseases.
Dr. Sinisa Dovat
Dr. Karmen Stankov
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- pediatrics
- novel therapy
- pathogenesis
- gene expression
- signal transduction
- precision medicine
- epigenetics
- oncogene
- tumor suppression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.